CJC-1295 no DAC / Ipamorelin Blend Reconstitution
Critical Issue: No FDA-Approved Formulation Exists
There are no FDA-approved reconstitution directions for CJC-1295 no DAC / Ipamorelin blend because this combination is not an FDA-approved pharmaceutical product. These peptides are research compounds that have not completed clinical trials or received regulatory approval for human use 1, 2.
Background on These Compounds
CJC-1295 (without DAC)
- CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of 29 amino acids with a C-terminal amide function 1
- The compound without the Drug Affinity Complex (DAC) modification has a much shorter half-life than the DAC version, which normally binds covalently to serum albumin 3, 4
- CJC-1295 is classified as a Prohibited Substance under Section S2 of the WADA Prohibited List as a growth hormone releasing factor 1
Ipamorelin
- Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue 2
- It stimulates GH release via a GHRP-like receptor with high potency and efficacy 2
- Unlike other GHRPs, ipamorelin does not significantly affect ACTH, cortisol, FSH, LH, PRL, or TSH levels, making it uniquely selective for GH release 2
Why Standard Reconstitution Guidance Cannot Be Provided
No medical guidelines, FDA drug labels, or peer-reviewed clinical protocols exist for reconstituting this peptide blend because it is not approved for human therapeutic use. The available evidence consists only of:
- Detection methods for anti-doping control 1, 3, 5
- Animal research studies 4
- Basic pharmacological characterization 2
Important Safety Considerations
These compounds are being manufactured and distributed illicitly, often before completing or even entering clinical trials 1. The risks include:
- Unknown purity and contamination of non-pharmaceutical grade products 1
- Lack of established safety profiles in humans for this specific combination
- Potential for adverse effects on the hypothalamic-pituitary axis
- Legal and regulatory violations, as these are prohibited substances in competitive sports 1
Any reconstitution instructions found outside of FDA-approved channels should not be followed, as they lack regulatory oversight and quality assurance.